** Ireland-based commercial stage biotechnology company Trinity Biotech's TRIB.O shares rise 8.7% to $0.73 premarket
** Co says it will strengthen focus on its Continuous Glucose Monitoring (CGM) technology
** Says that the successful execution of its comprehensive transformation plan is expected to drive near-term profitability improvements
** Co also appoints Barclays as its exclusive financial advisor to support strategic realignment
** Up to Wednesday's close, stock had fallen 22.7% so far this year
(Reporting by Anushka Chourasia)
((Anushka.Chourasia@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。